A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors Journal Articles Refereed uri icon

Overview

Authors

  • Authorship

Published in

  • Cancer Chemotherapy and Pharmacology

Time

Date/time value

  • 2010

Identity

Digital Object Identifier (DOI)

  • 10.1007/s00280-009-1188-1

Additional Document Info

Parent Title

  • CANCER CHEMOTHERAPY AND PHARMACOLOGY

Volume

  • 65

Issue

  • 4

Publisher

  • Springer Verlag